

RESEARCH

Open Access

# Expanding the phenotypic spectrum of *ARID1B*-mediated disorders and identification of altered cell-cycle dynamics due to *ARID1B* haploinsufficiency

Joe C H Sim<sup>1†</sup>, Susan M White<sup>1,2†</sup>, Elizabeth Fitzpatrick<sup>1</sup>, Gabrielle R Wilson<sup>1,2</sup>, Greta Gillies<sup>1</sup>, Kate Pope<sup>1</sup>, Hayley S Mountford<sup>1</sup>, Pernille M Torring<sup>3</sup>, Shane McKee<sup>4</sup>, Anneke T Vulto-van Silfhout<sup>5</sup>, Shalini N Jhangiani<sup>6</sup>, Donna M Muzny<sup>6</sup>, Richard J Leventer<sup>1,2,7</sup>, Martin B Delatycki<sup>1,2,8</sup>, David J Amor<sup>1,2</sup> and Paul J Lockhart<sup>1,2\*</sup>

## Abstract

**Background:** Mutations in genes encoding components of the Brahma-associated factor (BAF) chromatin remodeling complex have recently been shown to contribute to multiple syndromes characterised by developmental delay and intellectual disability. *ARID1B* mutations have been identified as the predominant cause of Coffin-Siris syndrome and have also been shown to be a frequent cause of nonsyndromic intellectual disability. Here, we investigate the molecular basis of a patient with an overlapping but distinctive phenotype of intellectual disability, plantar fat pads and facial dysmorphism.

**Methods/results:** High density microarray analysis of the patient demonstrated a heterozygous deletion at 6q25.3, which resulted in the loss of four genes including AT Rich Interactive Domain 1B (*ARID1B*). Subsequent quantitative real-time PCR analysis revealed *ARID1B* haploinsufficiency in the patient. Analysis of both patient-derived and *ARID1B* knockdown fibroblasts after serum starvation demonstrated delayed cell cycle re-entry associated with reduced cell number in the S<sub>1</sub> phase. Based on the patient's distinctive phenotype, we ascertained four additional patients and identified heterozygous *de novo* *ARID1B* frameshift or nonsense mutations in all of them.

**Conclusions:** This study broadens the spectrum of *ARID1B* associated phenotypes by describing a distinctive phenotype including plantar fat pads but lacking the hypertrichosis or fifth nail hypoplasia associated with Coffin-Siris syndrome. We present the first direct evidence in patient-derived cells that alterations in cell cycle contribute to the underlying pathogenesis of syndromes associated with *ARID1B* haploinsufficiency.

**Keywords:** Intellectual disability, Chromatin remodelling, Coffin-Siris syndrome, ARID1B mutation, Cell cycle, Haploinsufficiency

## Introduction

The control of gene expression is an intricately regulated process that requires many multiprotein complexes. Chromatin remodeling regulates gene expression by modulating the access of transcription machinery proteins to the condensed genomic DNA via dynamic modification of the

chromatin architecture. This modification is mediated by either covalent histone modifications via specific enzymes such as histone acetyltransferases or ATP-dependent alteration of DNA-nucleosome topology [1]. The latter mode of modification is mediated by a class of protein complexes called ATP-dependent chromatin-remodeling complexes, which are known to regulate gene expression in specific cellular contexts or at defined time points [2]. Recent studies have linked mutations in these complexes to both developmental disorders and cancer [3]. Mutations in *ARID1B* and several other genes encoding components

\* Correspondence: paul.lockhart@mcri.edu.au

†Equal contributors

<sup>1</sup>Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia

<sup>2</sup>Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3052, Australia

Full list of author information is available at the end of the article

of the Brahma-associated factor (BAF, also referred to as switching defective and sucrose nonfermenting SWI/SNF- $\alpha$ ) chromatin remodeling complex, were recently shown to cause Coffin-Siris syndrome (CSS) [4,5]. Subsequent studies have demonstrated that mutations in *ARID1B* are the main cause of CSS [6-8]. CSS is characterised by intellectual disability, severe speech impairment, coarse facial features, microcephaly, developmental delay and hypoplastic nails on the fifth digits (MIM 135900). However, *ARID1B* mutations have also been identified in a broader cohort of patients, including nonsyndromic intellectual disability and deletions in individuals with intellectual disability, autism and agenesis of the corpus callosum [9-11]. It is unclear as to why patients with *ARID1B* mutations present such a broad phenotypic spectrum.

*ARID1B* encodes a DNA-binding protein component of the ubiquitous ATP-dependent chromatin remodeling BAF complex, which is known to regulate gene expression, including genes involved in proliferation and differentiation [12]. These complexes are made up of at least ten core proteins and have fifteen known interchangeable components to give rise to an array of functionally distinct and cell-type specific BAF complexes, such as neuronal progenitor BAF complex [12,13]. Thus, mutations in different BAF components are likely to perturb the function of BAF complexes to varied degrees in different cell types. In agreement with this notion, a striking feature of mutations in the BAF components is the phenotypic variability presented by the patients [6,7]. To date, the biological processes affected in patients with *ARID1B* mutations are largely unknown.

Here, we report *ARID1B* haploinsufficiency in five patients with moderate intellectual disability, absent speech and dysmorphic features with narrow palpebral fissures, long eyelashes, a thin upper lip and full lower lip. Alterations in cell cycle were observed in fibroblasts derived from a patient and *ARID1B*-knockdown control fibroblast cells. Our study broadens the phenotypic spectrum of *ARID1B*-mediated disorders and provides the first evidence that alterations in cell cycle contribute to the underlying pathogenesis of syndromes associated with *ARID1B* haploinsufficiency.

## Methods

### Patients

Informed consents were obtained from patients' parents for the publication of clinical, genetic and molecular analyses. After receiving institutional Ethics Committee (Royal Children's Hospital, Melbourne, Australia) blood and tissue samples were obtained. Genomic DNA was extracted from whole blood using the BACC DNA extraction kit (GE Healthcare Life Sciences) according to the manufacturer's instructions. Standard karyotype analysis was performed using G-banding and high

density SNP array data (Affymetrix Human SNP array 6.0) was analysed for copy number variation using Karyo-studio (Illumina).

### Generation of *ARID1B* knockdown human fibroblast

Primary fibroblast cultures were established using standard procedures and maintained in BME supplemented with 10% fetal bovine serum (FBS). MicroRNA-adapted shRNA (shRNAmir)-mediated knockdown of *ARID1B* was performed using lentivirus containing *ARID1B*-targeting shRNAmir (V3THS\_306691 or V3THS\_306692, Open Biosystems) or scrambled non-silencing control (RHS4743, Open Biosystem). The lentiviral particles were generated by transfecting HEK293FT with V3THS\_306691, V3THS\_306692 or RHS4743 plasmids, and SPAX2 (Addgene) and pMD2.G (Addgene) lentiviral packaging plasmids using Lipofectamine 2000 (Invitrogen) according to manufacturers' instructions. The viral supernatants were harvested after 48 hours and concentrated at 70,000 g, 4°C for 2 hours. Wildtype fibroblasts were transduced with both V3THS\_306691 (MOI = 20) and V3THS\_306692 (MOI = 20) or RHS4743 (MOI = 20) to generate *ARID1B*-knockdown and non-silencing control fibroblast lines respectively. Transduced cells were cultured in complete media containing 4  $\mu$ g/ml puromycin for 2 weeks and transduction of the fibroblast lines was confirmed by expression of the co-expressed marker protein turboRFP.

### Quantitative real-time PCR analysis

Fibroblast cells were cultured in 60 cm dish and RNA was extracted using SV Total RNA Isolation system (Promega) according to manufacturer's instructions. 100 ng RNA was used to generate cDNA library for each sample using Transcriptor cDNA First Strand Synthesis kit (Roche) according to manufacturer's instructions. Real-time PCR reactions were performed in triplicate with Light Cycler 480II instrument (Roche) using Taqman probes directed against *ARID1B* (Applied Biosystems, hs00368175) and the housekeeping control Human Large Ribosomal Protein (*RPL0*) (Applied Biosystems, 432631E-0904009) and Fast Start Taqman Probe Master Mix (Roche) according to manufacturer's instructions. The relative *ARID1B* expression was analysed using Pfaffl method with respect to *RPL0* expression [14]. Standard deviations were calculated using Gaussian error propagation. T-Test was used to investigate the difference in relative *ARID1B* expression between samples. Each experiment was independently performed at least three times.

### Serum starvation assay

Fibroblasts were cultured in 60 cm dishes and incubated in serum free media for seven days to induce cell cycle arrest. Subsequently, complete media (10% FBS) was

added and cells were incubated for up to two days prior to FACS analysis to quantify the number of cells undergoing  $S_1$  phase. Cells were detached, fixed with 80% ethanol and incubated with propidium iodide/RNase A staining solution (50  $\mu$ g propidium iodide/ml, 0.2 mg RNase A/ml, 0.05% Triton-X100 in PBS) for 2 hours prior to Fluorescence-Activated Cell Sorting (FACS) analysis. A minimum of 10,000 cells were counted for each sample using BD LSR II Flow Cytometer (BD science) with excitation laser set at 488 nm and emission filter set at 695 nm/40 and analysed using ModFit LT analysis software (Verity Software House). Each experiment was independently performed at least three times.

### Sanger sequencing of ARID1B and whole Exome sequencing

Exons of *ARID1B* were amplified via PCR with primer sets listed in Additional file 1: Table S1. The resulting PCR products were purified and sequenced using BigDye Terminator kit v3.1 (Applied Biosystem) and ABI 3730 DNA Analyzer (Applied Biosystems). Exome sequencing of patient 5 was performed on an Illumina Hiseq 2000 platform with the NimbleGen VCRome 2.1 exome capture design for enrichment. The 125 bp paired-end reads were mapped to UCSC genome Browser Hg 19 and variants and indels were called using HGSC Mercury analysis pipeline [15]. High quality variant calls were filtered on nonsynonymous changes in the coding regions or changes affecting the canonical splice sites. Variants that were present with a frequency above 1% in dbSNP and the Nijmegen in-house database containing data of over 1,300 exomes, or in 200 exomes analysed using the same Illumina Hiseq 2000 platform were excluded.

## Results


### Identification of patient 1


Patient 1 presented with moderate intellectual disability, absent speech and dysmorphic features with narrow palpebral fissures, long eyelashes, a thin upper lip and

full lower lip. Fetal finger and toe pads and plantar lipomas were present (Figure 1A-C). Karyotype analysis showed an apparently balanced *de novo* reciprocal translocation involving chromosomes 4 and 6 (46,XY,t(4;6)(q35;q25.3)) in all examined cells ( $n = 15$ ). The chromosome 4 breakpoint was located within a 0.3 Mb region that did not encode any genes, whereas the chromosome 6 breakpoint was mapped to a  $\sim$ 0.4 Mb region that encoded several genes. Copy number analysis did not identify any variations associated with the chromosome 4 breakpoint. However, a heterozygous deletion of  $\sim$ 1.2 Mb was identified on 6q25.3 that resulted in single allele loss of the genes encoding sorting nexin-9 (SNX9), zinc finger DHHC-type containing 14 (ZDHHC14), transmembrane protein 242 (TMEM242) and AT rich interactive domain 1B (ARID1B) (Figure 2).

### ARID1B haploinsufficiency in patient 1

Given the documented role of *ARID1B* in disorders with a clinical presentation somewhat similar to our patient, we tested the effect of the deletion on *ARID1B* expression in patient-derived primary fibroblasts. Western blot analysis using multiple commercially available antibodies directed against ARID1B failed to robustly identify the predicted  $\sim$ 240 kDa protein in patient or control fibroblast cells (data not shown). However, real-time PCR analysis revealed that the transcription level of *ARID1B* in patient 1 was significantly reduced ( $35 \pm 7\%$ , mean  $\pm$  SD,  $n = 5$ ,  $P < 0.001$ ) in comparison to the control fibroblasts (Figure 3A). In order to further characterise the effect of *ARID1B* haploinsufficiency, we utilised a knockdown approach. Wildtype fibroblasts co-transduced with *ARID1B*-targetting shRNAmir (V3THS\_306691 and V3THS\_306692) expressed *ARID1B* mRNA at approximately 60% of control levels ( $56 \pm 12\%$ , mean  $\pm$  SD,  $n = 3$ ,  $P < 0.01$ ). In contrast, no effect on *ARID1B* mRNA level was observed when the non-silencing control was utilised (Figure 3A).






### Entry to S<sub>1</sub> phase is delayed in patient 1

It was previously demonstrated that ARID1B deficiency delayed cell cycle re-entry after cell cycle arrest induced by serum starvation in mouse MC3T3 osteoblasts [16]. To investigate whether the molecular defect in patient 1 might lead to similar deficits, we analysed the kinetics of cell cycle re-entry after serum starvation [17]. Control fibroblasts showed a peak in cells undergoing S<sub>1</sub> phase (21% ± 4.5, mean ± SD, n = 6) at 20 hours post serum replenishment (Figure 3B). In contrast, the percentage of cells undergoing S<sub>1</sub> phase at 20 hours post serum replenishment was significantly lower in both patient 1 (1.5% ± 0.35, mean ± SD, n = 3, P = 0.0002) and 90090-

KD (9.6% ± 1.7, mean ± SD, n = 3, P = 0.005) compared to control. The maximum number of patient 1 cells in S<sub>1</sub> phase (5.4 ± 2.1%, mean ± SD, n = 3) was observed 30 hours post serum replenishment. Similarly, knock-down of *ARID1B* in control fibroblasts resulted in a delayed entry to S<sub>1</sub> phase, with the peak also occurring at 30 hours post serum replenishment. The number of cells undergoing S<sub>1</sub> phase in the knockdown fibroblasts at 30 hours post serum replenishment was greater than observed in patient 1. This may be because there was a trend to elevated *ARID1B* mRNA (and presumably protein) compared to patient 1, although it was not of statistical significance (Figure 3A). Both patient 1 and the



knockdown cells demonstrated significantly reduced mRNA levels compared to the control fibroblasts and control fibroblasts transduced with the non-silencing ‘scramble’ control. While off-target effects were not specifically controlled for, the non-silencing control cells did not display alterations in either the number or timing of cells undergoing S<sub>1</sub> phase. Moreover, both patient and ARID1B-knockdown cells displayed similar delayed entry to S<sub>1</sub> phase, suggesting the effects were due to reduced ARID1B rather than a non-specific off target effect of the *ARID1B*-targetting shRNA used. Although we could not definitively demonstrate reduced endogenous ARID1B levels by western blot (antibodies tested were sc-32762 and NB100-57484), collectively these observations suggested that reduced ARID1B was associated with perturbed cell cycle regulation, which affected both the number and timing of cells entering S<sub>1</sub> phase after serum starvation.

#### Identification of four additional patients with *ARID1B* mutations





The distinctive clinical features observed in patient 1 enabled us to ascertain four additional patients with a strikingly similar phenotype. All five patients, including patient 1 had intellectual disability, absent speech, plantar fat pads, fetal finger pads, and facial dysmorphism, consisting of narrow palpebral fissures, long eyelashes, a thin upper lip and full lower lip (Table 1). Direct sequencing of genomic DNA revealed that three additional patients encoded *de novo* single allelic *ARID1B* mutations; NM\_020732.3 (*ARID1B*):c.3208\_3209delAA (p.(Lys1070Alafs\*47)) in patient 2, NM\_020732.3 (*ARID1B*):c.2306\_2308delCCGinsT CCGCAGCCACTCC (p.(Pro769Leufs\*17)) in patient 3 and NM\_020732.3 (*ARID1B*):c.4273dupT (p.(Tyr1425Leu

fs\*34)) in patient 4. Whole exome sequencing of patient 5 identified 325 unique variants. Further filtering against an in-house database of genes previously implicated in intellectual disability identified a single candidate variant, which is predicted to be truncating. The *de novo* heterozygous *ARID1B* mutation NM\_020732.3 (*ARID1B*):c.2941C > T (p.(Gln981\*)) was confirmed by Sanger sequencing (Figure 4). Two of these patients (patient 3 and patient 5) were previously published as having a phenotype consistent with Pierpont syndrome [18]. The molecular basis of Pierpont syndrome remains to be reported, but plantar fat pads are a key feature. The facial features in the five patients described here are distinct from those originally reported in Pierpont syndrome in that their palpebral fissures are not as narrow and their nasal tip not as broad [18,19]. Therefore we now believe their diagnosis should be of a BAF complex disorder due to *ARID1B* haploinsufficiency. In addition, we carried out mutation analysis of *ARID1B* (but not other members of the BAF complex) in four patients with classical features of Pierpont syndrome including patient 1 of the original case report [19] and did not identify any mutation (unpublished data).

#### Discussion

Recent reports have demonstrated that mutations in *ARID1B* can cause both nonsyndromic intellectual disability and CSS. The phenotypes associated with *ARID1B* haploinsufficiency are variable but common features of the syndromic and nonsyndromic cases include intellectual disability and speech impairment. While the facial dysmorphism and intellectual disability present in our cohort is similar to previously published patients with *ARID1B* mutations [4-7], this study broadens the spectrum of *ARID1B*-associated phenotypes because all


**Table 1 Comparison of patient clinical features**

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
					
Previously published	-	-	Patient 5 in Wright et al, 2011 [18]	-	Patient 6 in Wright et al, 2011 [18]
Age at assessment	8y	2y	6y 10m	5y	8y 2m
Height centile	50th	10-25th	25th	3rd	2nd
Weight centile	50-75th	25th	50-75th	25th	2nd
Head circumference	50-98th	25th	50-98th	25th	50th
Heel Fat pads	+	+	+	+	+
Fetal finger and toe pads	+	+	+	NR	+
Fifth nail hypoplasia	-	-	-	-	-
Hirsutism	-	-	-	-	+
ID	Mod	Mod	Mild	Mod	Mod
Speech	Absent	Absent	Delayed	Absent	Delayed
Seizures	-	+	-	+	-
Drooling	+	+	+	-	+
Feeding difficulty	+	-	Mild	-	-
Scoliosis	-	-	-	-	+
Inguinal hernia	-	-	-	-	-
Neuroimaging	Mega cisterna magna on brain MRI	Normal brain MRI	Hypoplastic posterior elements of corpus callosum on MRI	Head CT in first year of life, normal	Normal

our patients presented with plantar fat pads and fetal finger/toe pads and none of our patients have the fifth nail hypoplasia hallmark of CSS. As some of the previous cohorts with *ARID1B* mutations were ascertained by a clinical diagnosis of CSS, there is a selection bias in the phenotypic features they will have. Although none of the point mutations in *ARID1B* are common between CSS and our cohort, three CSS-like patients with *de novo* single allelic deletion at chromosome 6 similar to patient 1 were identified by Santen *et al.* in a large cohort of patients with intellectual disability [4]. The phenotypes of these patients share some features but apparently represent distinct syndromic manifestations of *ARID1B* haploinsufficiency. Thus, our cohort demonstrates that the *ARID1B* phenotypic spectrum is broader than previously defined and includes the novel clinical features of plantar fat pads and fetal digit pads. The constant features across cohorts appear to be the facial gestalt and the presence of

intellectual disability particularly affecting speech, in contrast to the marked variability in the presence and type of manifestations in the hands and feet.

*ARID1B* is a DNA-binding component of BAF complexes that are involved in regulating many biological pathways [12]. However, the repertoire of pathways regulated by these BAF complexes and the impact of mutations in BAF components on these pathways are still poorly understood. Here, we present the first direct evidence in patient-derived cells that alterations in cell cycle may contribute to the pathogenesis of syndromes associated with *ARID1B* haploinsufficiency. Given that the BAF complex comprises over 25 core and interchangeable protein subunits that give rise to functionally distinct and cell-type specific complexes [12], it is likely that additional variation in these components contributes to the observed phenotypic variability in *ARID1B*-mediated disorders.



**Figure 4 Analysis of *ARID1B* in the patient cohort.** The protein domain organisation of *ARID1B* and the position of the four mutations identified by sequencing are shown. The forward and reverse sequencing traces demonstrate the NM\_020732.3(*ARID1B*):c.3208\_3209delAA (p.(Lys1070Alafs\*47)) mutation in patient 2 (A), the NM\_020732.3(*ARID1B*):c.2306\_2308delCCGinsTCCGCAGCCACTCC (p.(Pro769Leufs\*17)) mutation in patient 3 (B), the NM\_020732.3(*ARID1B*):c.4273dupT (p.(Tyr1425Leufs\*34)) mutation in patient 4 (C) and the NM\_020732.3(*ARID1B*):c.2941C > T (p.(Gln981\*)) mutation in patient 5 (D). Where available, the forward sequencing trace for the parents is also shown. Mutation co-ordinates are derived from refseq NM\_020732.3.

It is possible that the developmental features observed in patients with *ARID1B* haploinsufficiency are the result of abnormal regulation of cell cycle re-entry of developmentally arrested cells. This would impair developmental processes by upsetting the initiation of progenitor cell proliferation. In support of this notion, homozygous knockout of *arid1b* in mouse is embryonic lethal but the ES cells demonstrated a reduced proliferation rate and perturbation of differentiation and cell cycle [20]. An analogous observation is the presence of microcephaly in a minority of patients with *ARID1B* mutations and more broadly in Coffin-Siris syndrome [6,8]. Besides regulating cell cycle, chromatin-remodeling events and BAF complexes have been shown to be critically important during neural development and dendrite formation [13,21,22]. Although a specific role for *ARID1B* in early brain development remains to be demonstrated, the gene is predominantly expressed in neural tissues in the developing mouse embryo, suggesting that it is important for development of the brain when multipotent neuroepithelial cells are actively proliferating [9,23]. Future studies should investigate if impaired neural development contributes to the intellectual disability and speech impairment that are consistently observed in patients with *ARID1B* haploinsufficiency.

## Conclusion

Our study demonstrates that the *ARID1B* phenotypic spectrum is broader than previously defined and includes the novel clinical features of plantar fat pads and fetal digit pads. These features can manifest in the absence of the hypertrichosis or fifth nail hypoplasia associated with Coffin-Siris syndrome. In addition, we present the first direct evidence in patient-derived cells that alterations in cell cycle may contribute to the underlying pathogenesis of syndromes associated with *ARID1B* haploinsufficiency.

## Additional file

**Additional file 1: Table S1.** Details of primer sequences. Primers were designed to amplify DNA encoding *ARID1B* (NM\_020732.3) for direct sequence analysis.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JS performed molecular analysis and co-wrote the manuscript. SW provided and interpreted the clinical data and co-wrote the manuscript. EF, GW, GG, HM, SJ and DM performed molecular analysis and interpreted data. KP performed patient recruitment and read/contributed to the manuscript. PT, ATvS, SM, RJL, MBD and DJA provided and interpreted the clinical data and

revised the manuscript. P.J.L. collected and analysed the data, wrote the manuscript and is responsible for overall content as guarantor and corresponding author.

#### Acknowledgements

We thank the families for their participation in this study and the generous support of the Lefroy and Handbury families. We thank Professor Han Brunner, Professor Di Donnai, Professor Raoul Hennekam, Dr Marlies Kempers, Dr Maria Kibaek, Dr Sahar Mansour, Dr Ann Olney, Dr Mary Ella Pierpont and Dr Emma Wright for their contribution of patients for this study. We also thank Professors Richard A. Gibbs and James R. Lupski for input into the manuscript.

#### Funding

This work was funded in part by National Health and Medical Research Council Australia Program Grant 490037 to DJA. MBD is supported by an NHMRC Practitioner Fellowship (546452) and P.J.L. is supported by an NHMRC Career Development Fellowship (APP1032364). This study was accomplished in part through the Centers for Mendelian Genomics research effort funded by the National Institutes of Health and supported by the National Human Genome Research Institute grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.

#### Author details

<sup>1</sup>Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia. <sup>2</sup>Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3052, Australia. <sup>3</sup>Department of Clinical Genetics, Odense University Hospital, University of Southern Denmark, Odense, Denmark. <sup>4</sup>Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK. <sup>5</sup>Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>6</sup>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA. <sup>7</sup>Department of Neurology, Royal Children's Hospital, Parkville, Victoria 3052, Australia. <sup>8</sup>Clinical Genetics, Austin Health, Heidelberg, Victoria 3084, Australia.

Received: 3 December 2013 Accepted: 10 March 2014  
Published: 27 March 2014

#### References

1. Teif VB, Rippe K: Predicting nucleosome positions on the DNA: combining intrinsic sequence preferences and remodeler activities. *Nucleic Acids Res* 2009, **37**:5641–5655.
2. Liu N, Balliano A, Hayes JJ: Mechanism(s) of SWI/SNF-induced nucleosome mobilization. *Chembiochem* 2011, **12**:196–204.
3. Wilson BG, Roberts CW: SWI/SNF nucleosome remodellers and cancer. *Nat Rev Cancer* 2011, **11**:481–492.
4. Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CA, van Ommen GJ, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M: Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat Genet* 2012, **44**:379–380.
5. Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y, Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H, Miyake N, et al.: Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat Genet* 2012, **44**:376–378.
6. Wiczorek D, Bogershausen N, Beleggia F, Steiner-Haldenstatt S, Pohl E, Li Y, Milz E, Martin M, Thiele H, Altmüller J, Alanay Y, Kayserili H, Klein-Hitpass L, Böhringer S, Wollstein A, Albrecht B, Boduroglu K, Caliebe A, Chrzanosowska K, Cogulu O, Cristofoli F, Czeschik JC, Devriendt K, Dotti MT, Elcioglu N, Gener B, Goecke TO, Krajewska-Walasek M, Guillén-Navarro E, Hayek J: A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. *Hum Mol Genet* 2013, **22**(25):5121–5135.
7. Santen GW, Aten E, Vulto-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout IJ, Snowdowne R, van der Lans CA, Boogaard M, Linssen MM, Vijfhuizen L, van der Wielen MJ, Vollebregt MJ, Coffin-Siris consortium,

- Breuning MH, Kriek M, van Haeringen A, den Dunnen JT, Hoischen A, Clayton-Smith J, de Vries BB, Hennekam RC, van Belzen MJ: Coffin-Siris Syndrome and the BAF Complex: Genotype-Phenotype Study in 63 Patients. *Hum Mutat* 2013, **34**:1519–1528.
8. Tsurusaki Y, Okamoto N, Ohashi H, Mizuno S, Matsumoto N, Makita Y, Fukuda M, Isidor B, Perrier J, Aggarwal S, Tsurusaki Y, Okamoto N, Ohashi H, Mizuno S, Matsumoto N, Makita Y, Fukuda M, Isidor B, Perrier J, Aggarwal S, Dalal AB, Al-Kindy A, Liebelt J, Mowat D, Nakashima M, Saitsu H, Miyake N, Matsumoto N: Coffin-Siris syndrome is a SWI/SNF complex disorder. *Clin Genet* 2013. DOI:10.1111/cge.12225.
  9. Backx L, Seuntjens E, Devriendt K, Vermeesch J, Van Esch H: A balanced translocation t(6;14)(q25.3;q13.2) leading to reciprocal fusion transcripts in a patient with intellectual disability and agenesis of corpus callosum. *Cytogenet Genome Res* 2011, **132**:135–143.
  10. Halgren C, Kjaergaard S, Bak M, Hansen C, El-Schich Z, Anderson CM, Henriksen KF, Hjalgrim H, Kirchhoff M, Bijlsma EK, Nielsen M, den Hollander NS, Ruivenkamp CA, Isidor B, Le Caignec C, Zannolli R, Mucciolo M, Renieri A, Mari F, Anderlid BM, Andrieux J, Dieux A, Tommerup N, Bache I: Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. *Clinical genetics* 2012, **82**:248–255.
  11. Hoyer J, Ekici AB, Ende S, Popp B, Zweier C, Wiesener A, Wohlleb E, Dufke A, Rossier E, Petsch C, Zweier M, Göhring I, Zink AM, Rappold G, Schröck E, Wiczorek D, Riess O, Engels H, Rauch A, Reis A: Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. *Am J Hum Genet* 2012, **90**:565–572.
  12. Hargreaves DC, Crabtree GR: ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. *Cell Res* 2011, **21**:396–420.
  13. Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R, Graef IA, Crabtree GR: An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* 2007, **55**:201–215.
  14. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 2001, **29**:e45.
  15. Lupski JR, Gonzaga-Jauregui C, Yang Y, Bainbridge MN, Jhangiani S, Buhay CJ, Kovar CL, Wang M, Hawes AC, Reid JG, Eng C, Muzny DM, Gibbs RA: Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy. *Genome medicine* 2013, **5**:57.
  16. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E: Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. *EMBO J* 2007, **26**:752–763.
  17. Davis PK, Ho A, Dowdy SF: Biological methods for cell-cycle synchronization of mammalian cells. *BioTechniques* 2001, **30**:1322–1326. 1328, 1330–1321.
  18. Wright EM, Suri M, White SM, de Leeuw N, Vulto-van Silfhout AT, Stewart F, McKee S, Mansour S, Connell FC, Chopra M, Kirk EP, Devriendt K, Reardon W, Brunner H, Donnai D: Pierpont syndrome: a collaborative study. *Am J Med Genet A* 2011, **155A**:2203–2211.
  19. Pierpont ME, Stewart FJ, Gorlin RJ: Plantar lipomatosis, unusual facial phenotype and developmental delay: a new MCA/MR syndrome. *Am J Med Genet* 1998, **75**:18–21.
  20. Yan Z, Wang Z, Sharova L, Sharov AA, Ling C, Piao Y, Aiba K, Matoba R, Wang W, Ko MS: BAF250B-associated SWI/SNF chromatin-remodeling complex is required to maintain undifferentiated mouse embryonic stem cells. *Stem cells* 2008, **26**:1155–1165.
  21. Wu JI, Lessard J, Olave IA, Qiu Z, Ghosh A, Graef IA, Crabtree GR: Regulation of dendritic development by neuron-specific chromatin remodeling complexes. *Neuron* 2007, **56**:94–108.
  22. Ho L, Crabtree GR: Chromatin remodelling during development. *Nature* 2010, **463**:474–484.
  23. Flores-Alcantar A, Gonzalez-Sandoval A, Escalante-Alcalde D, Lomeli H: Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle. *Cell Tissue Res* 2011, **345**:137–148.

doi:10.1186/1750-1172-9-43

Cite this article as: Sim et al.: Expanding the phenotypic spectrum of ARID1B-mediated disorders and identification of altered cell-cycle dynamics due to ARID1B haploinsufficiency. *Orphanet Journal of Rare Diseases* 2014 **9**:43.